Bank of America Corp DE lifted its holdings in Sanofi (NASDAQ:SNY – Free Report) by 17.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,626,939 shares of the company’s stock after purchasing an additional 1,541,832 shares during the quarter. Bank of America Corp DE owned about 0.42% of Sanofi worth $578,318,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in SNY. Fairfield Bush & CO. acquired a new stake in shares of Sanofi in the 1st quarter worth $26,000. Bank of New York Mellon Corp boosted its position in shares of Sanofi by 31.3% in the 1st quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock worth $22,623,000 after purchasing an additional 105,046 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Sanofi by 12.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock worth $1,264,000 after purchasing an additional 2,805 shares in the last quarter. Yousif Capital Management LLC boosted its position in shares of Sanofi by 45.2% in the 1st quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock worth $2,158,000 after purchasing an additional 13,095 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Sanofi by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock worth $15,402,000 after purchasing an additional 1,391 shares in the last quarter. Institutional investors and hedge funds own 10.06% of the company’s stock.
Sanofi Trading Up 0.7 %
NASDAQ SNY opened at $53.03 on Friday. The company has a fifty day moving average of $52.91 and a 200 day moving average of $53.63. The company has a market capitalization of $133.89 billion, a PE ratio of 18.16, a P/E/G ratio of 1.57 and a beta of 0.57. Sanofi has a 1 year low of $36.91 and a 1 year high of $57.82. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on SNY shares. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 29th. HSBC began coverage on shares of Sanofi in a report on Friday, July 14th. They set a “buy” rating on the stock. Finally, Berenberg Bank raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $79.33.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- ESG Stocks, What Investors Should Know
- What More Does Chewy Have to Do to Impress Investors?
- Most Volatile Stocks, What Investors Need to Know
- These 3 Wood Stocks are about to go on Discount
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.